-DOCSTART- -X- O
Viruses -X- _ O
of -X- _ O
the -X- _ O
family -X- _ O
Filoviridae -X- _ B-Patient
represent -X- _ O
significant -X- _ O
health -X- _ O
risks -X- _ O
as -X- _ O
emerging -X- _ O
infectious -X- _ O
diseases -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
potentially -X- _ O
engineered -X- _ O
biothreats. -X- _ O
While -X- _ O
many -X- _ O
research -X- _ O
efforts -X- _ O
have -X- _ O
been -X- _ O
published -X- _ O
offering -X- _ O
possibilities -X- _ O
toward -X- _ O
the -X- _ O
mitigation -X- _ O
of -X- _ O
filoviral -X- _ O
infection -X- _ O
, -X- _ O
there -X- _ O
remain -X- _ O
no -X- _ O
sanctioned -X- _ O
therapeutic -X- _ O
or -X- _ O
vaccine -X- _ O
strategies. -X- _ O
Current -X- _ O
progress -X- _ O
in -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
filovirus -X- _ B-Intervention
therapeutics -X- _ I-Intervention
and -X- _ I-Intervention
vaccines -X- _ I-Intervention
is -X- _ O
outlined -X- _ O
herein -X- _ O
with -X- _ O
respect -X- _ O
to -X- _ O
their -X- _ O
current -X- _ O
level -X- _ O
of -X- _ O
testing -X- _ O
, -X- _ O
evaluation -X- _ O
, -X- _ O
and -X- _ O
proximity -X- _ O
toward -X- _ O
human -X- _ O
implementation -X- _ O
, -X- _ O
specifically -X- _ O
with -X- _ O
regard -X- _ O
to -X- _ O
human -X- _ O
clinical -X- _ O
trials -X- _ O
, -X- _ O
nonhuman -X- _ O
primate -X- _ O
studies -X- _ O
, -X- _ O
small -X- _ O
animal -X- _ O
studies -X- _ O
, -X- _ O
and -X- _ O
in -X- _ O
vitro -X- _ O
development. -X- _ O
Contemporary -X- _ B-Intervention
methods -X- _ I-Intervention
of -X- _ I-Intervention
supportive -X- _ I-Intervention
care -X- _ I-Intervention
and -X- _ O
previous -X- _ O
treatment -X- _ O
approaches -X- _ O
for -X- _ O
human -X- _ O
patients -X- _ O
are -X- _ O
also -X- _ O
discussed -X- _ O
. -X- _ O

